WINTON GROUP Ltd Makes New $7.38 Million Investment in Exelixis, Inc. $EXEL

WINTON GROUP Ltd acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 4th quarter, Holdings Channel.com reports. The fund acquired 168,437 shares of the biotechnology company’s stock, valued at approximately $7,383,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Exelixis by 81.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after purchasing an additional 19,407 shares during the period. Goldman Sachs Group Inc. lifted its stake in Exelixis by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock worth $54,153,000 after acquiring an additional 68,133 shares during the period. Focus Partners Wealth lifted its stake in Exelixis by 83.4% in the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after acquiring an additional 17,483 shares during the period. Geneos Wealth Management Inc. lifted its stake in Exelixis by 134.3% in the first quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 944 shares during the period. Finally, Sivia Capital Partners LLC raised its holdings in Exelixis by 23.8% in the second quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock worth $633,000 after purchasing an additional 2,764 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director George Poste sold 60,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $45.71, for a total transaction of $2,742,600.00. Following the transaction, the director owned 118,832 shares in the company, valued at $5,431,810.72. This represents a 33.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Dana Aftab sold 43,451 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the transaction, the executive vice president owned 594,741 shares in the company, valued at approximately $29,945,209.35. This trade represents a 6.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 219,170 shares of company stock valued at $10,620,641. 2.60% of the stock is owned by company insiders.

Exelixis Stock Up 0.4%

EXEL opened at $52.70 on Friday. Exelixis, Inc. has a 52-week low of $33.76 and a 52-week high of $52.98. The company has a market cap of $13.25 billion, a P/E ratio of 17.51, a price-to-earnings-growth ratio of 1.51 and a beta of 0.41. The firm’s 50-day moving average price is $46.96 and its 200-day moving average price is $44.53.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm had revenue of $610.81 million for the quarter, compared to the consensus estimate of $607.51 million. During the same quarter in the prior year, the company posted $0.55 earnings per share. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. On average, research analysts anticipate that Exelixis, Inc. will post 3.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EXEL. Morgan Stanley boosted their target price on shares of Exelixis from $49.00 to $50.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a report on Tuesday, May 19th. TD Cowen boosted their target price on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Stifel Nicolaus boosted their target price on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company upped their price objective on shares of Exelixis from $35.00 to $40.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $47.35.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.